2021 Networking Pharmaceutical research Safety 
European Pharmaceutical Review
SEPTEMBER 22, 2023
7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.
Pharmaceutical Technology
MARCH 6, 2023
Based on preclinical research for their impact on aging, well-known drugs like metformin and rapamycin are already being considered for off-label usage, due to their accepted safety profile and cost-effectiveness. We need to act decisively now and start to do the research really diligently.”
Expert insights. Personalized for you.
77 
Let's personalize your content